Physician profile
Shanda Schroeder
NPI 1952973190
$547.01
in general payments reported to CMS, 2019-2025
12 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.15 · 2023: $81.34 · 2024: $164 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $115.90 | 2024-2025 | Myfembree |
| Abbvie INC. | $96.49 | 2023-2025 | |
| Pfizer INC. | $63.26 | 2024-2025 | |
| Astellas Pharma US INC | $59.08 | 2024-2025 | Veozah |
| Biogen, INC. | $50.20 | 2025 | Zurzuvae |
| Becton, Dickinson and Company | $38.02 | 2025 | Bd Onclarity |
| Merck Sharp & Dohme LLC | $37.50 | 2024-2025 | Gardasil 9, Gardasil |
| Pacira Pharmaceuticals Incorporated | $24.45 | 2025 | Exparel |
| Janssen Pharmaceuticals, INC | $17.10 | 2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $16.12 | 2025 | |
| Novo Nordisk INC | $15.74 | 2023 | |
| Davol INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanda Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.